Cover Image

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on the use of primary chemoimmunotherapy to treat patients with locally advanced or recurrent endometrial cancer = Stellungnahme der Kommission Uterus der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) zur primären Chemo- Immuntherapie bei Patientinnen mit lokal fortgeschrittenem oder rezidiviertem Endometriumkarzinom

The publication of two large randomized studies - the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial and the NRG-GY018 trial - which investigated combining chemotherapy with immunotherapy to treat patients with primary advanced or recurrent endometrial cancer (EC) has transformed the clinical study landscape i...

Full description

Saved in:
Bibliographic Details
Main Authors: Tempfer, Clemens (Author) , Brucker, Sara (Author) , Juhasz-Böss, Ingolf Hardy Geza (Author) , Mallmann, Peter (Author) , Steiner, Eric (Author) , Denschlag, Dominik (Author) , Hillemanns, Peter (Author) , Wallwiener, Markus (Author) , Beckmann, Matthias Wilhelm (Author)
Format: Article (Journal)
Language:English
Published: 12. September 2023
In: Geburtshilfe und Frauenheilkunde
Year: 2023, Volume: 83, Issue: 9, Pages: 1095-1101
ISSN:1438-8804
DOI:10.1055/a-2145-1545
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1055/a-2145-1545
Verlag, kostenfrei, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-2145-1545
Get full text
Author Notes:authors: Clemens Tempfer, Sara Brucker, Ingolf Juhasz-Boess, Peter Mallmann, Eric Steiner, Dominik Denschlag, Peter Hillemanns, Markus Wallwiener, Matthias W. Beckmann, for the Uterus Commission of the Ago
Description
Summary:The publication of two large randomized studies - the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial and the NRG-GY018 trial - which investigated combining chemotherapy with immunotherapy to treat patients with primary advanced or recurrent endometrial cancer (EC) has transformed the clinical study landscape in terms of first-line therapy for affected patients and has set a new standard of therapy. In the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial, the addition of dostarlimab to standard chemotherapy with carboplatin and paclitaxel resulted in. In the NRG-GY018 trial, the addition of pembrolizumab to standard chemotherapy with carboplatin and paclitaxel resulted in</p> <p>As expected, the effect in both trials was much more pronounced in the group of patients with dMMR/MSI-high tumors. According to the assessment of the Uterus Organ Commission of the AGO, all patients with dMMR/MSI-high tumors should receive chemoimmunotherapy and all patients with pMMR/MSI-low tumors who meet the inclusion criteria of the two trials discussed here may have chemoimmunotherapy.
Item Description:Gesehen am 06.08.2024
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-2145-1545

Similar Items